Last reviewed · How we verify

Primary hemophagocytic lymphohistiocytosis — Treatment Landscape & Competitive Intelligence

Primary hemophagocytic lymphohistiocytosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary hemophagocytic lymphohistiocytosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Gamifant EMAPALUMAB Novimmune S.A. Interferon gamma Blocker [EPC] Interferon gamma 2018-01-01
Emapalumab-Lzsg Emapalumab-Lzsg Swedish Orphan Biovitrum Interferon gamma Blocker [EPC] Interferon gamma

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novimmune S.A. · 1 drug in Primary hemophagocytic lymphohistiocytosis
  2. Swedish Orphan Biovitrum · 1 drug in Primary hemophagocytic lymphohistiocytosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary hemophagocytic lymphohistiocytosis:

Cite this brief

Drug Landscape (2026). Primary hemophagocytic lymphohistiocytosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-hemophagocytic-lymphohistiocytosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing